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The capacity for self-renewal is thought to be a critical property of tumor-initiating cells. This capacity is often
associated with the ability to generate spheres in vitro. In this issue of Cancer Cell, Barrett et al. show that
cells lacking sphere-forming ability can still be very efficient at propagating tumors.One of the great frustrations of current
cancer therapy is that the disease often
returns even after aggressive surgery,
radiation, and chemotherapy. Conse-
quently, the discovery of unique popula-
tions of tumor cells that may be respon-
sible for recurrence—and that could be
targeted to prevent it–has garnered a
great deal of interest. These cells, termed
tumor-initiating cells (TICs) or cancer
stem cells, were originally defined based
on their ability to reinitiate tumors fol-
lowing transplantation. However, studies
from a variety of systems have shown
that TICs frequently share characteristics
with normal stem cells, including marker
expression, ability to self-renew, and
ability to give rise to progeny of multiple
lineages. Because FACS analysis and
in vitro assays of self-renewal are much
simpler than in vivo studies of tumorige-
nicity, the former are sometimes used as
a surrogate for the latter.
One system in which TICs have been
studied extensively is glioma. Numerous
reports have suggested that glioma
intiating cells share markers with neural
stem cells (NSCs), and that when cul-
tured at low density in the presence of
growth factors, they can give rise to clon-
ally-derived ‘‘tumorspheres,’’ analogous
to the neurospheres generated when
NSCs are cultured under similar condi-
tions. In fact, the ability of glioma cells to
self-renew under neurosphere conditions
has prompted many investigators to pro-
pagate patient samples as spheres
rather than as traditional adherent cell
lines (Galli et al., 2004; Lee et al., 2006).
However, the assumption that all gliomas
can be propagated by stem-like sphere-
forming cells has not been carefully
tested.In this issue ofCancer Cell, Barrett et al.
(Barrett et al., 2012) show that in a sub-
set of gliomas, cells that lack stem cell
markers and are unable to form spheres
are more tumorigenic than cells that
have these properties.
The investigators used a model of
glioma in which mice lacking the Arf
tumor suppressor gene were injected
with viruses encoding platelet-derived
growth factor (PDGF) or its downstream
signaling mediator KRAS (Fomchenko
et al., 2011). Because the PDGF pathway
is aberrantly activated in the ‘‘proneural’’
form of human glioma (Verhaak et al.,
2010), this model has been used to
study that subtype of the disease. To
investigate the relationship between
self-renewal and tumor initiation, they
crossed their animals with Id1VenusYFP
reporter mice (Nam and Benezra, 2009).
This allowed them to separate cells
based on expression of Id1, a transcrip-
tional regulator that has been shown to
control self-renewal in NSCs. Consistent
with the role of Id1 in NSCs, Id1high
cells (which represented <1% of tumor
cells) were enriched in expression of
stem cell markers (e.g., Prominin-1/
CD133), and were very efficient at sphere
formation. In contrast, Id1low cells ex-
pressed progenitor markers (e.g., Olig2,
Mash1, NG2), and showed minimal self-
renewal capacity in the sphere assay
(Figure 1).
The investigators then sorted Id1high
and Id1low tumor cells and tested their
ability to give rise to tumors following
transplantation. Surprisingly, the ability
to form spheres in vitro did not corre-
late with in vivo tumorigenic potential.
Although Id1high and Id1low cells could
both generate tumors, Id1low cells didCancer Cellso much more quickly and with higher
penetrance. For example, in the KRAS-
driven model of glioma, Id1low cells
generated tumors in 52% of mice, with
a latency of 37 days, whereas Id1high
cells gave rise to tumors in only 5%
of mice, with a latency of 119 days.
These studies suggested that sphere-
forming cells are not necessarily more
tumorigenic.
To determine if Id1 function is required
for tumor growth, Barrett et al. (2012)
crossed their animals to Id1 knockout
mice or to mice expressing a conditional
allele of Id1 that could be deleted using
Cre recombinase. In both cases, they
found that loss of Id1 dramatically im-
paired sphere formation but did not
affect tumorigenicity. In contrast, knock-
down of Olig2 (a progenitor marker that
is enriched in Id1low cells and has been
shown to be required for glioma forma-
tion [Ligon et al., 2007]) significantly
impaired tumor formation. These studies
reinforce the notion that in vitro self-
renewal may not be linked to tumorigenic
potential.
The disconnect between sphere
formation and tumorgenicity has a num-
ber of important implications. First, it
highlights the fact that not all tumor-
propagating cells resemble stem cells.
Whereas normal NSCs expand when
cultured under neurosphere conditions,
normal progenitors typically do not.
Thus, tumors that are propagated by
progenitor-like TICs would not be ex-
pected to grow under these conditions.
This is supported by studies of tumors
in Patched mutant mice, a model
for Sonic hedgehog-driven medulloblas-
toma; these tumors are propagated
by progenitor-like CD15+ cells that21, January 17, 2012 ª2012 Elsevier Inc. 1
Figure 1. Distinct Populations of Cells Mediate Sphere Formation and Tumor Initiation
PDGF- and KRAS-driven gliomas contain mixtures of cells expressing high and low levels of the
transcription factor Id1. Id1high cells (orange) are much more efficient than Id1low cells (pink) at forming
self-renewing spheres in vitro. In contrast, Id1low cells are much more efficient at forming tumors following
transplantation into mice. (Illustration by Jill Gregory.)
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neurosphere conditions (Read et al.,
2009). Importantly, if not all TICs can
form spheres, using this approach to
expand patient tumor samples might
result in a significant selection bias;
only tumors that can form spheres would
be available for study. Indeed, one
recent study noted that only half of
primary gliomas were able to give
rise to tumorsphere lines (Chen et al.,
2010).
Even when tumors can be grown
under sphere-forming conditions, the
cells that grow out may not be represen-
tative of the original tumor. As Barrett
et al. (2012) show, these conditions
may select for subpopulations of cells
(i.e., Idhigh cells) that do not represent
the full tumorigenic potential of the orig-
inal tumor. In addition to selection,2 Cancer Cell 21, January 17, 2012 ª2012 Elculturing cells at low density in the pres-
ence of growth factors may change their
behavior. This was shown many years
ago for NSCs, which can undergo
marked changes in cell fate potential
when cultured under neurosphere condi-
tions (Gabay et al., 2003). Barrett et al.
(2012) provide further evidence for this,
by showing that glioma cells cultured as
spheres undergo changes in marker
expression (including Id1 and Olig2) and
lose the ability to generate tumors upon
transplantation. The fact that culture
conditions can dramatically alter tumori-
genic potential raises cautions about
using tumorspheres to screen for drugs
that might be effective at killing tumors
in patients.
One possible interpretation of the
disconnect between sphere-forming ca-
pacity and tumorigenic potential is thatsevier Inc.tumor initiation does not depend on self-
renewal. However, the fact that Id1low
cells cannot form spheres in vitro does
not necessarily mean that they cannot
self-renew. It is possible that under the
appropriate culture conditions, these cells
might show extensive self-renewal. More
importantly, the fact that Id1low cells can
form tumors following transplantation
indicates that they are capable of signifi-
cant expansion in vivo. The degree to
which this expansion involves self-
renewal (e.g., by asymmetric division)
versus differentiation remains to be deter-
mined. Moreover, the ability of Id1low
tumor cells to serially transplant tumors
without exhausting—another measure of
in vivo self-renewal–has not been tested.
Further studies may shed light on the
capacity of Id1low tumor cells to self-
renew in vivo.
It is important to note that these
studies focus on a specific subtype of
glioma and that other forms of glioma
may be propagated by stem-like,
sphere-forming cells. At the same time,
it is worth considering whether other
types of cancer that are propagated as
spheres might be subject to the same
caveats raised by these studies. As con-
venient as cultured cell lines can
be for studying tumor biology, it is
critical to remember that tumors only
grow in living animals. Finding ways to
make them stop growing often re-
quires moving beyond the in vitro
sphere and into the complex in vivo
microenvironment.REFERENCES
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In this issue of Cancer Cell, Gajjar et al. provide insight into how Mdm2 can both inhibit and enhance p53
activity. In the basal setting, Mdm2 binds p53 and promotes p53 degradation. Under stress conditions,
ATM-dependent phosphorylation of Mdm2 results in its recruitment to p53 mRNA, thereby stimulating p53
translation.The p53 tumor suppressor is a transcrip-
tion factor that is induced in response to
a variety of stress signals (Kruse and Gu,
2009). Under normal conditions, the p53
protein is kept at low levels in cells by
ubiquitination-dependent proteosomal
degradation mediated by its negative
regulator, the E3 ubiquitin ligase Mdm2
(Figure 1A). Mdm2 is also a p53 transcrip-
tional target and thus participates in
a negative feedback loop with p53.
Stress-mediated upregulation of Mdm2
has been considered a means by which
p53 is able to regulate the duration and
amplitude of its cellular effects.
In response to activation of specific
oncogenic pathways, the ARF tumor
suppressor is upregulated. ARF, in turn,
interferes with Mdm2-dependent inhibi-
tion of p53 (Manfredi, 2010) (Figure 1B).
In contrast, stimulation of the p53
pathway by genotoxic stress involves
the DNA damage-activated kinase ATM,
which has been shown to directly phos-
phorylate both p53 and Mdm2 (Kruse
andGu, 2009;Manfredi, 2010) (Figure 1C).
The significance of ATM-dependent
phosphorylation of Mdm2 was confirmed
by the observation that phosphorylation
of serine 395 on Mdm2 led to impaired
p53 degradation (Maya et al., 2001).
Biochemical studies have indicated that
this is likely due to altered oligomerization,thereby attenuating the processivity of the
E3 ligase activity of Mdm2 (Cheng et al.,
2009). DNA damage has also been shown
to induce the relocalization of Mdm2 to
the nucleolus (Bernardi et al., 2004). It
has been proposed that a nucleotide-
binding motif within the Mdm2 E3 ligase
RING domain facilitates nucleolar locali-
zation of Mdm2 (Poyurovsky et al.,
2003). Candeias et al. (2008) then made
the surprising observation that the p53
mRNA itself was able to interact directly
with the RING domain of Mdm2. This
interaction impaired the E3 ligase activity
of Mdm2 and promoted p53 mRNA trans-
lation. It was unclear, however, under
what biological settings such an interac-
tion would have relevance.
In this issue of Cancer Cell, Gajjar et al.
(2012) provide important insight by
demonstrating that the DNA damage-
and ATM-dependent phosphorylation of
Mdm2 on serine 395 promotes the inter-
action of Mdm2 with p53 mRNA. This, in
turn, is needed for p53 stabilization and
apoptotic activity (Gajjar et al., 2012)
(Figure 1D). BymeansofRNAi andoverex-
pression experiments, these authors
show that both ATM and Mdm2 are
required to achieve full p53 apoptotic
activity after DNA damage. Use of an
Mdm2 isoform that does not bind to the
p53 protein shows that a protein-proteininteraction between Mdm2 and p53 is
remarkably dispensable for this. It was
further demonstrated that the interaction
between p53 mRNA and the Mdm2 RING
domain is necessary for p53-dependent
apoptosis after genotoxic stress. Studies
using a mutated p53mRNA that no longer
binds Mdm2 confirmed findings with
amutantMdm2protein that has a reduced
affinity for the mRNA. These intriguing
results support the notion that ATM-medi-
ated phosphorylation of Mdm2 at serine
395 promotes allosteric changes in the
RING domain, which in turn facilitate p53
mRNA binding. Finally, Gajjar et al. (2012)
show that after DNA damage, the interac-
tion between Mdm2 and p53 mRNA
impairs Mdm2-dependent ubiquitination
of p53. Thus, it is argued that the p53
mRNA-MDM2 interaction not only
increases p53 translation but also inhibits
p53 protein degradation as well.
In sum, this study demonstrates that
Mdm2 can act as a positive regulator of
p53 activity after genotoxic stress. It
further provides an additional novel expla-
nation for why Mdm2 is transcriptionally
upregulated by p53 after DNA damage.
The finding that p53 mRNA relocalizes
with Mdm2 in the nucleolus after DNA
damage is especially interesting since
the nucleolus is generally thought of as
the site of ribosomal RNA transcription.21, January 17, 2012 ª2012 Elsevier Inc. 3
